Nuevocor Secures $45 Million to Advance Innovative Cardiomyopathy Treatment
Nuevocor, a biotechnology company headquartered in Singapore, has successfully closed a $45 million Series B financing round aimed at advancing its innovative therapy for cardiomyopathy driven by aberrant mechanobiology. This round was co-led by Kurma Partners and Angelini Ventures, with backing from existing investors such as EDBI, ClavystBio, and the Boehringer Ingelheim Venture Fund, among others.
The fresh funds will facilitate the commencement of a Phase 1/2 clinical trial for their lead candidate, NVC-001, targeted at patients diagnosed with LMNA-related dilated cardiomyopathy (LMNA DCM). This specific form of cardiomyopathy affects over 100,000 people across the U.S. and Europe, resulting from mutations in the LMNA gene which cause heart muscle degeneration and potentially lead to severe conditions like heart failure. The study will be conducted across multiple clinical sites in both the United States and Europe.
Dr. Yann Chong Tan, CEO and Co-Founder of Nuevocor, expressed his enthusiasm regarding the new funding milestone. He lauded the decision of notable investors to come onboard and emphasized that such support would allow Nuevocor to maintain its momentum and propel NVC-001 into clinical development. The company's innovative approach exemplifies Singapore's commitment to transforming healthcare through cutting-edge solutions.
The investment from Kurma Partners and Angelini Ventures underscores a strategic expansion into the realm of cardiovascular diseases, particularly gene therapies that promise to address not just the symptoms, but the underlying mechanobiological pathways contributing to these ailments. "Nuevocor offers hope to cardiovascular patients who currently find themselves with limited treatment options," stated Dr. Amanda Gett-Chaperot of Kurma Partners. She highlighted the importance of Nuevocor’s approach in targeting the fundamental causes of disease, rather than merely addressing superficial symptoms.
NVC-001 stands out as a pioneering gene therapy designed to combat LMNA DCM through a one-time intervention that aims to restore the structural integrity of the nuclear envelope, which is a hallmark of this disease. Preclinical studies of NVC-001 have shown promising results, indicating notable survival advantages and safety profiles, paving the way for its anticipated Phase 1/2 trials.
The company plans to initiate these trials in early 2026, further supporting its broader goal of establishing a local presence in Europe through a new office in Paris. This strategic move aims to consolidate their clinical development efforts and connect innovations from Singapore with patients worldwide.
With the backing of established investors, Nuevocor's trajectory is poised to bring groundbreaking treatments to market. As healthcare increasingly leans towards personalized and targeted therapies, the company's platform appears to sell the promise of advanced treatment modalities that go beyond current standard therapies. Their vision revolves around addressing the root causes of genetic cardiomyopathies, which have previously remained underserved within the biotech sector.
Nuevocor is also gaining momentum by positioning itself at the forefront of biotechnology, leveraging its proprietary PrOSIATM mechanobiology platform to explore therapies for various conditions associated with cardiomyopathy, not just those amendable to conventional gene replacement approaches.
As part of the financial backing by Kurma Partners and Angelini Ventures, the biomedical community anticipates that the growth of Nuevocor will signify a vital step towards fostering more intricate solutions within the landscape of genetic-heart disease treatments. The company's progress may culminate in a significant impact across healthcare arenas, showcasing the innovative capacity of Singaporean biotechnology on the global stage.
The fresh funds will facilitate the commencement of a Phase 1/2 clinical trial for their lead candidate, NVC-001, targeted at patients diagnosed with LMNA-related dilated cardiomyopathy (LMNA DCM). This specific form of cardiomyopathy affects over 100,000 people across the U.S. and Europe, resulting from mutations in the LMNA gene which cause heart muscle degeneration and potentially lead to severe conditions like heart failure. The study will be conducted across multiple clinical sites in both the United States and Europe.
Dr. Yann Chong Tan, CEO and Co-Founder of Nuevocor, expressed his enthusiasm regarding the new funding milestone. He lauded the decision of notable investors to come onboard and emphasized that such support would allow Nuevocor to maintain its momentum and propel NVC-001 into clinical development. The company's innovative approach exemplifies Singapore's commitment to transforming healthcare through cutting-edge solutions.
The investment from Kurma Partners and Angelini Ventures underscores a strategic expansion into the realm of cardiovascular diseases, particularly gene therapies that promise to address not just the symptoms, but the underlying mechanobiological pathways contributing to these ailments. "Nuevocor offers hope to cardiovascular patients who currently find themselves with limited treatment options," stated Dr. Amanda Gett-Chaperot of Kurma Partners. She highlighted the importance of Nuevocor’s approach in targeting the fundamental causes of disease, rather than merely addressing superficial symptoms.
NVC-001 stands out as a pioneering gene therapy designed to combat LMNA DCM through a one-time intervention that aims to restore the structural integrity of the nuclear envelope, which is a hallmark of this disease. Preclinical studies of NVC-001 have shown promising results, indicating notable survival advantages and safety profiles, paving the way for its anticipated Phase 1/2 trials.
The company plans to initiate these trials in early 2026, further supporting its broader goal of establishing a local presence in Europe through a new office in Paris. This strategic move aims to consolidate their clinical development efforts and connect innovations from Singapore with patients worldwide.
With the backing of established investors, Nuevocor's trajectory is poised to bring groundbreaking treatments to market. As healthcare increasingly leans towards personalized and targeted therapies, the company's platform appears to sell the promise of advanced treatment modalities that go beyond current standard therapies. Their vision revolves around addressing the root causes of genetic cardiomyopathies, which have previously remained underserved within the biotech sector.
Nuevocor is also gaining momentum by positioning itself at the forefront of biotechnology, leveraging its proprietary PrOSIATM mechanobiology platform to explore therapies for various conditions associated with cardiomyopathy, not just those amendable to conventional gene replacement approaches.
As part of the financial backing by Kurma Partners and Angelini Ventures, the biomedical community anticipates that the growth of Nuevocor will signify a vital step towards fostering more intricate solutions within the landscape of genetic-heart disease treatments. The company's progress may culminate in a significant impact across healthcare arenas, showcasing the innovative capacity of Singaporean biotechnology on the global stage.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.